atabecestat

an oral BACE1 inhibitor

Also Known As:

2-pyridinecarboxamide, N-(3-((4S)-2-amino-4-methyl-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-cyano-; JNJ-54861911; N-(3-((4S)-2-Amino-4-methyl-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-cyano-2-pyridinecarboxamide

Networked: 8 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - atabecestat: 8
  - Thiazines: 3
    - atabecestat: 8
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazines: 3
    - atabecestat: 8

Experts

1.	Henley, David: 3 articles (01/2021 - 11/2019)
2.	Bogert, Jennifer: 2 articles (01/2021 - 01/2020)
3.	Brashear, H Robert: 2 articles (01/2021 - 01/2020)
4.	Novak, Gerald: 2 articles (01/2021 - 01/2020)
5.	Raghavan, Nandini: 2 articles (01/2021 - 11/2019)
6.	Raman, Rema: 2 articles (01/2021 - 11/2019)
7.	Romano, Gary: 2 articles (01/2021 - 11/2019)
8.	Sperling, Reisa: 2 articles (01/2021 - 11/2019)
9.	Engelborghs, Sebastiaan: 2 articles (01/2020 - 01/2018)
10.	Russu, Alberto: 2 articles (01/2020 - 01/2018)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 01/01/2020 - "Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study." 11/01/2019 - "Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease." 01/01/2018 - "Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study." 01/01/2021 - "Atabecestat is an orally administered BACE inhibitor developed to treat Alzheimer's disease. " 09/01/2023 - "Atabecestat, a potent brain penetrable BACE1 inhibitor that reduces CSF amyloid beta (Aβ), was developed as an oral treatment for Alzheimer's disease (AD). "
2.	Cognitive Dysfunction 01/01/2018 - "In two similarly designed phase I studies, a sample of amyloid-positive elderly patients comprising 45 Caucasian patients with early AD diagnosed as preclinical AD (n = 15, Clinical Dementia Rating [CDR] = 0) or with mild cognitive impairment due to AD (n = 30, CDR = 0.5) and 18 Japanese patients diagnosed as preclinical AD (CDR-J = 0) were randomized 1:1:1 to atabecestat 10 or 50 mg or placebo (n = 6-8/treatment) daily for 4 weeks. " 01/01/2021 - "Atabecestat, a nonselective oral β-secretase inhibitor, was evaluated in the EARLY trial for slowing cognitive decline in participants with preclinical Alzheimer disease. "
3.	Chemical and Drug Induced Liver Injury 01/01/2021 - "Biopsy Pathology and Immunohistochemistry of a Case of Immune-Mediated Drug-Induced Liver Injury With Atabecestat."
4.	Inflammation (Inflammations) 09/01/2023 - "The suggestive GWAS signals in the case-control GWAS analysis suggest the potential role of inflammation in atabecestat-induced liver enzyme elevation."
5.	Dementia (Dementias) 01/01/2018 - "We present proof of mechanism of atabecestat (also known as JNJ-54861911), an oral BACE inhibitor for the treatment of AD, in Caucasian and Japanese populations with early AD who do not show signs of dementia. "

Related Drugs and Biologics

1.	Amyloid (Amyloid Fibrils)
2.	Amyloid Precursor Protein Secretases (beta-Secretase)
3.	Amyloid beta-Peptides
4.	Biomarkers (Surrogate Marker)
5.	Enzymes